By proceeding, you agree to our Terms of Use and Privacy Policy.
Welcome to the 6th Obesity & NASH Drug Development Summit There has been a rise and fall of investment in NASH in the wake of highly demanding biopsy endpoints and late-stage clinical setbacks.
Harness advances in GLP - 1 receptor agonists to drive drug based management of obesity.
Forge a deeper understanding of multifactorial pathogenesis of NASH and interrogate the interrelationships between obesity, cardiometabolism & NAFLD.
Participate in panel discussions and networking sessions to connect with peers and industry experts.
Hear from 150+ industry experts unraveling mechanisms of injury and repair, establishing a clinical pathway.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations.
Visualizing the Future – Minimizing risk Antaros Medical is an entirely unique service provider. We are pioneering new frontiers in innovative MRI/PET imaging techniques, seamless clinical drug development and understanding of human pathophysiology.
Nordic Bioscience is the leading expert in extracellular matrix (ECM) research with 25+ years of experience in biomarker development, pre-clinical and clinical research.
OM1 is a leading health outcomes and registries company focused on the measurement, comparison, and prediction of treatment outcomes.
Physiogenex is a leading preclinical contract research organization (CRO) specializing in metabolic disorders such as diabetes, obesity, liver diseases, dyslipidemia, atherosclerosis and cardiovascular complications.
Cerba Research is the merge of Barc Lab, Histalim and Cerba Xpert. All 3 entities are part of the Cerba HealthCare group and have decided to join forces under one name.
FibroFind is a rapidly developing biomedical sciences company that has a deep understanding of fibrosis biology and has employed this knowledge to design bespoke biological assays with human tissues that can determine if a novel drug is able to preve
Perspectum's imaging solutions are safe, fast, and can offer more comprehensive diagnostics. We help doctors understand complex data and help deliver precision care to more patients. We believe the voice of the.
HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.